Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243862 · ClinicalTrials.gov registry record · Phase 2
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
A Phase 2 study of Colorectal Cancer Metastatic, sponsored by Treos Bio Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT05243862 is a Phase 2 study of Colorectal Cancer Metastatic that is active but no longer recruiting, run by Treos Bio Limited. The registered enrollment target is 18 participants, below the 204-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05243862, a Phase 2 study of Colorectal Cancer Metastatic, is active but no longer recruiting, sponsored by Treos Bio Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimens.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG PolyPEPI1018
Study Locations (3)
Arizona
- Mayo Clinic - Phoenix
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243862
The ClinicalTrials.gov registry entry for NCT05243862 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (91% lower). The listed sponsor is Treos Bio Limited, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05243862 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05243862 about?
NCT05243862 is a clinical study titled "Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.". This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimens.
What is the current status of trial NCT05243862?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-06-02. Estimated completion is 2026-06-02.
What conditions does trial NCT05243862 study?
This clinical trial studies the following conditions: Colorectal Cancer Metastatic.
What interventions are being tested in trial NCT05243862?
The interventions under investigation include: Atezolizumab (DRUG), PolyPEPI1018 (DRUG).
Who is sponsoring clinical trial NCT05243862?
This trial is sponsored by Treos Bio Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05243862 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
-
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.